CellFE – a life sciences tools company developing a microfluidics-based cell engineering platform dedicated to transforming the development and manufacturing of advanced cell therapies – recently announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures and Riverine Ventures and existing investors Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital, and Khosla Ventures.
The continued clinical and commercial success of advanced biologic therapeutics like engineered cell and gene therapies drives substantial growth opportunities in this emerging life sciences segment. Therapy developers are forging partnerships with technology providers like CellFE to advance innovative solutions to benefit patients seeking better therapeutic options.
CellFE’s innovative, non-viral, microfluidic cell engineering platform, Infinity MTx system, performs complex genetic cell editing through streamlined, advanced workflows. This platform ensures gentle cell treatment, rapid cell recovery, and superior yield of healthy cells, enabling unparalleled scalability and significant time and cost efficiencies in development and manufacturing.
Plus, CellFE empowers therapy developers to accelerate the evolution of advanced cell therapies across a spectrum of therapeutic areas, unlocking a groundbreaking shift towards true decentralized and point-of-care manufacturing in the cell therapy sector. The launch of the Infinity MTx system at the recent ASGCT 2023 Annual Meeting elicited broad interest from top innovative cell therapy developers globally.
KEY QUOTES:
“With our clear path to help redefine cell therapy manufacturing, we are excited to have the backing of such esteemed investors who recognize the potential of our technology and the strength of our team. Our vision of advancing the platform to a decentralized and point-of-care application will expand access to cell therapies for millions of patients.”
– Alla Zamarayeva, CEO of CellFE
“While viral cell engineering methods have been dominating the industry to date, high costs, limited editing capabilities, regulatory hurdles, and safety concerns are driving a shift to non-viral methods. CellFE presents a unique technology platform addressing key industry pain points across viral, but also other non-viral methods. Offering efficient, flexible, and consistent payload delivery, superior cell health, user-friendly workflows, and process scalability from development to manufacturing, we believe the company offers a compelling value proposition for the increasing number of therapy developers seeking novel solutions. We are delighted to join the company that Alla and the CellFE team have built at this exciting time and to support the company’s future development, growth, and overall vision.”
– Christian Uhrich, Principal at M Ventures
